Universidade Federal De Minas Gerais

Fundacao Oswaldo Cruz

Ricardo Tostes Gazzinelli

Eduardo Antonio Ferraz Coelho

Rafael Polidoro Alves Barbosa

Braulia Costa Caetano

Alexandre De Magalhaes Vieira Machado

Oscar Bruna-Romero

Flavio Fonseca Guimaraes

Erica Araujo Mendes

Ana Paula Salles Moura Fernandes

Christiane De Freitas Abrantes

Oscar BRUÑA-Romero

ÉRica Araújo Mendes

Flávio Fonseca GUIMARÃES

The present invention concerns to recombinant influenza viruses and modified Vaccinia Ankara viruses (MVA), and to a process for construction of recombinant influenza viruses and modified vaccinia Ankara viruses (MVA) with genes that encode for theparasite SAGI (MVA) and SAG2 (MVA and influenza) proteins, by means of a homologous recombination technique between two transfer vectors (for construction of MVA virus) and reverse genetics (for construction of influenza virus). Additionally, the present invention describes a vaccine composition using recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), or recombinant adenoviruses and modified vaccinia Ankara viruses (MVA), for immunization against infections caused by theparasite.

[object Object]

The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, monophosphoryl lipid A, or aluminum hydroxide plus CpG as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of

Vaccine composition and immunization method

Growing community of inventors

Belo Horizonte, Brazil

Ricardo Tostes Gazzinelli